Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Spain / NCT06211907
Recruiting Not applicable

Small Macular Holes Treated With Air

NCT06211907 · tracked via the Priya Life Science Spain tracker
Sponsor
Helse Stavanger HF
Phase
Not applicable
Started
2024-07-14
Last updated
2024-11-06

Condition(s) studied

Macular Holes

Investigational drug(s) / intervention(s)

Postoperative intraocular tamponade

Postoperative intraocular tamponade: Flushing the eye cavity with a tamponade at the end of surgery

Study summary

Non-inferiority trial comparing intraocular air and gas tamponade for closure of macular holes.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Primary MH ≤250 μm * MH duration ≤12 months * No previous vitreoretinal surgery in study eye * Ability to sign informed consent * Signed informed consent * Age ˃18 years Exclusion Criteria: * Previous vitreoretinal surgery in study eye * Secondary MH caused by other conditions than vitreomacular traction * Myopic MH, i.e., excessive myopia (more than -6 dioptres) * Traumatic MH * MH secondary to retinal detachment or other retinal diseases * Previously participation in this study

Primary outcome measure(s)

  • Macular hole closure after single surgery — 4 weeks
    Closure verified on OCT

Trial sites (7)

FacilityCityRegionStatus
Department of Ophthalmology, University of Thessaly Thessaly Thessaly Not Yet Recruiting
Stavanger University Hospital Stavanger Rogaland Recruiting
University Hospital of Northern Norway Tromsø Troms Recruiting
St. Olavs University Hospital Trondheim Tronderlag Recruiting
Haukeland University Hospital Bergen Vestland Recruiting
Oslo University Hospital Oslo Norway Recruiting
Clinical Universitary Hospital of Santiago Santiago de Compostela La Coruna Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06211907 on ClinicalTrials.gov ↗ ← All trials in Spain